About
“The best investment is something everyone needs, no one can stop, and few understand.”
Michael Saylor uses this quote to reference investing in Apple/Amazon/Google in the late 2000s or Bitcoin in the 2010s, when almost no one, outside early adopters and visionaries, could see how dominant and pervasive these technologies would become.
Yes, it’s a framework for making money, but it’s also my personal philosophy about where I put my time and energy and what consistently holds my attention. I’m drawn to the edge of the newest, least understood ideas in technology and medicine, before a consensus forms. That’s what pulled me into healthcare, psychedelic medicine, bitcoin, energy, and technology/AI.
My experience across these fields spans many roles and projects. It’s given me a well-rounded skill set for navigating new environments, working through complexity, and solving problems. Below, I share more about my interests and experience in each area.
Healthcare
The early part of my career has been rooted in healthcare operations. In college, I pivoted from a pre-med path to healthcare management, bringing together my interests in medicine, healthcare, and business. That shift led me to Teladoc Health, the largest virtual-care company in the world.
Over this period, I’ve grown significantly, supported by mentors and shaped by roles across client experience and operations, program management, clinical operations, patient experience, and performance operations. I led several C-suite priorities, including implementing AI clinical transcription, internal referral, and gaps-in-care workflows in PRISM, Teladoc’s proprietary care delivery platform, and building a new performance operations function from the ground up. My work resulted in over $1.4M in annual cost savings and efficiencies, $1.3M+ in incremental revenue one year after launch, and resolution of a $3.6M cumulative reserve balance. I also led remediation of an at-risk client relationship that resulted in a $10M contract renewal and a $20M signed upsell opportunity within 12 months. The breadth of this work and the people I learned from gave me a strong foundation early in my career, and I’m grateful for both.
Psychedelic medicine
Driven by curiosity and my neuroscience background at the University of Pennsylvania, I’ve been drawn to the science of psychedelic medicine since 2021. In a neuroscience class on hallucinogens, including psilocybin and LSD, I first realized these “drugs” could have immense potential for healing and advancing science. I became fascinated by the contrast between the positive findings in recent clinical literature and my prior negative assumptions, shaped by mainstream perceptions.
Throughout my time at Penn, I continued learning to understand the roots of that disconnect better (see “Medicine in History (Health and Societies) Final Project - 2021”) and the broader science behind psychedelic medicine. A major personal inflection point was hearing personal healing stories directly from clinical trial participants during a seminar series at Penn, which, to this day, is a major source of motivation for my work in this industry.
Without an outlet to share this passion, I initially felt lost. That’s what led me to restart a psychedelic society during my graduate studies at Rutgers University (see “RU Psyched Club Manual”) and to expand this mission on a global scale through the Intercollegiate Psychedelics Network. Within a year at Rutgers, we recruited a team of 7 officers and 250+ members, and organized 9 educational events to advance responsible psychedelic discourse and community at Rutgers University. As a result, we were invited to join the New Jersey Psilocybin Coalition to support advocacy of NJS2283: Psilocybin Behavioral Health Access and Services Act. At IPN, we’ve grown to 2,100+ members across 70+ countries, supporting students’ professional growth and career development through hundreds of hours of free programming.
Today, I’m most passionate about expanding my reach in this space as psychedelic medicine enters the mainstream. I care about the path from clinical validation to mainstream access, and I look forward to opportunities to work with individuals and companies to deliver psychedelic therapy safely and efficiently at scale.
Investing & Markets (Bitcoin, Energy, AI & Technology)
In my spare time, I write and share market research at @jmjcapital covering individual companies, macroeconomics, Bitcoin, energy, technology, and psychedelic medicine. I enjoy understanding businesses from the inside out and forming a view before the consensus does.
As a neuroscience major, I didn’t have a traditional background in finance, markets, or economics, so I learned through friends, online communities, podcasts, books, and LLMs. That journey led me to create my X account, JMJ Capital, in 2021 as a more hands-on way to learn by absorbing information, engaging with others, and sharing my thinking.
The industries I research reflect my core philosophy: investing where asymmetry exists.
- Bitcoin: every form of money before it, from rai stones to metals to fiat, has failed on scarcity, portability, or decentralization, which is how governments have quietly debased currency for centuries, from Roman coin clipping to Venezuela's hyperinflation to today's cost-of-living crisis. Bitcoin is the first money that is scarce, portable, and decentralized at once, giving individuals real protection from that debasement. Most people dismiss it as magic internet money because they have never questioned the money they inherited.
- Energy: we're in the middle of an energy transformation, driven by electrification and AI's rising power demand. Solar, wind, and battery storage keep winning new grid capacity because they're cheap today and getting cheaper, driven by learning curves. I pay closest attention to battery storage, since it solves renewables' intermittency problem and enables us to get more out of existing energy infrastructure without additional transmission.
- AI & Technology: the loudest skeptics calling AI a bubble are rarely daily users of the tools. Pairing what I've seen since the release of Claude Opus 4.5 and OpenClaw with what I know about the physical constraints on the power grid pointed me to companies building AI infrastructure with the fastest time to power, which led me to companies like IREN, CIFR, and WULF in 2024.
Beyond building wealth, investing has sharpened how I see the world and how companies operate. Through investing, I’ve learned patience, discipline, risk management, and critical thinking - lessons I can carry into everything else I do.
AI & Technology
As a generalist, I used to feel disadvantaged, dependent on specialists like engineers to turn ideas into real products and tools. AI has changed that and has now become a large part of my work. Using tools like Claude Code, Codex, and open-source software, I’ve built a member web application, automated analytics infrastructure, and other interactive web applications. I also use AI across market research, analysis, product design, graphic design, and QA. Further developing these skills will only become more important, as I believe they accelerate product velocity and reduce barriers to entry for many businesses, which will lead to large-scale disruption and/or margin pressure.
You can see examples of my work in the Projects section of the website.
Have a project, role, or idea worth talking through?
I’m looking to work with passionate people and teams advancing healthcare, psychedelic medicine, and other emerging fields. If you’re hiring, building, or exploring an idea where my experience could help, let’s connect.